“It gives me goose bumps to be part of a team that has the potential to make such an incredible clinical and societal impact.”

Eleanor L. Ramos, MD, Chief Medical Officer, Provention Bio

about us

Executive Team

Ashleigh Palmer

Chief Executive Officer & Co-Founder

Ashleigh Palmer

Chief Executive Officer & Co-Founder

Ashleigh Palmer, co-founder of Provention and its CEO, is a life sciences industry entrepreneur and innovator with more than 30 years’ experience and expertise in corporate strategy formulation, preclinical and clinical drug evaluation and product development and commercialization. During his career, Mr. Palmer has served as CEO for multiple biopharma companies (both private and public) and has held numerous board director and chairman positions. In addition to Provention, Mr. Palmer currently serves as a non-executive director on the board of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide for certain life-threatening and debilitating critical care and chronic cardiopulmonary conditions. Mr. Palmer is also President of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry.

From 2015 through 2017, Mr. Palmer served as Executive Chairman of Celimmune, LLC, a clinical development-stage immunotherapy company he co-founded, dedicated to developing therapies for celiac disease and intestinal lymphoma. Celimmune was acquired by Amgen Inc. in November 2017.

Prior to founding Provention, Celimmune and CBV, Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, acquired by Mallinckrodt in 2015 for $2.3 billion.

Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Educated in the UK, Mr. Palmer received his MBA from the University of Bradford and his BSc honors in Biochemistry and Applied Molecular Biology from the University of Manchester.

Francisco Leon, MD, PhD

Chief Scientific Officer & Co-Founder

Francisco Leon, MD, PhD

Chief Scientific Officer & Co-Founder

Francisco Leon, MD, PhD is the scientific co-founder of Provention Bio, Inc. An immunologist by training, Dr. Leon brings to the Company a breadth of experience and expertise from his academic and industry careers in the fields of immunology and immune-mediated disease clinical research.

Previously, Dr. Leon was the co-founder, Chief Executive Officer and Chief Medical Officer of Celimmune, LLC, a clinical stage immunotherapy company dedicated to developing transformational therapies for celiac disease, intestinal lymphoma and other serious immune-mediated diseases. Celimmune was acquired by Amgen Inc. in November 2017.

Prior to Celimmune, Dr. Leon served as Vice President and Head of Translational Medicine/Immunology at Johnson & Johnson’s Janssen Pharmaceuticals, where he led early-stage clinical development in immunology. Dr. Leon’s professional experience is also highlighted by positions of increasing responsibility at several life sciences companies, including Chief Medical Officer of Alba Therapeutics, Director of Clinical Development, Inflammation & Respiratory at Medimmune/Astra Zeneca and Director of Clinical Discovery, Immunology & Oncology at Bristol-Myers Squibb. Dr. Leon led or played an important role in the early development of several approved products: Astra Zeneca’s benralizumab/FASENRA®; Bristol-Myers Squibb’s abatacept/ORENCIA® and belatacept/NULOJIX®; and Janssen’s ustekinumab/STELARA® and guselkumab/TREMFYA®.

Prior to entering the biopharma industry, Dr. Leon served as a Postdoctoral Fellow at the National Institutes for Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). In 2011, he became an Associate Professor of Medicine at Jefferson Medical College in Philadelphia, where he continues to contribute to the clinical research efforts of the Department of Gastroenterology. Dr. Leon earned his MD and PhD from Autónoma University, and his specialization in Clinical Immunology from Ramon y Cajal Hospital, both in Madrid, Spain. He has authored or co-authored more than 80 peer-reviewed articles, book chapters and patents.

Eleanor L. Ramos, MD

Chief Medical Officer

Eleanor L. Ramos, MD

Chief Medical Officer

Eleanor L. Ramos, MD, brings 25 years of biopharmaceutical experience to her role as Chief Medical Officer of Provention. Her background includes significant clinical expertise in autoimmunity, inflammation, organ transplant rejection and the treatment of acute and chronic viral infections.

Prior to joining Provention, Dr. Ramos served as a Chief Medical Officer of Global Blood Therapeutics (GBT), a publicly-traded biopharmaceutical company dedicated to developing novel therapeutics to treat blood-based disorders. Her past experience includes roles as Chief Medical Officer of Theraclone Sciences, a therapeutic antibody discovery and development company, where she oversaw the development of clinical programs in viral diseases including severe influenza, and as Chief Medical Officer at ZymoGenetics, overseeing its clinical portfolio across infectious diseases/hepatitis C, immunology/lupus nephritis, oncology and hemostasis. In addition, Dr. Ramos’ career spans director-level positions at leading pharmaceutical companies including Roche Global Development and Bristol-Myers Squibb.

Dr. Ramos led or played an important role in the development of several approved products: Roche’s mycophenolate mofetil/CellCept® and daclizumab/Zenapax®; Bristol-Myers Squibb’s belatacept/NULOJIX®; and ZymoGenetics recombinant thrombin/RECOTHROM®.

Dr. Ramos is currently a member of the Scientific Advisory Board of EpiVax Oncology, a private biotechnology company focused on developing personalized cancer vaccines, and a member of the Board of Directors of ASK About Lung Cancer, a non-profit organization dedicated to increasing awareness of lung cancer in women, particularly those of Asian descent. Her experience also encompasses leading the Clinical Trials Group at the Immune Tolerance Network, a collaborative network for clinical research funded by the National Institute of Allergy and Infectious Diseases. She holds a medical degree and undergraduate degree from Tufts University, along with advanced training in the subspecialty of nephrology with a focus on transplantation immunology at Brigham and Women’s Hospital, Harvard Medical School.

Andrew Drechsler

Chief Financial Officer

Andrew Drechsler

Chief Financial Officer

Andrew Drechsler brings more than 20 years of financial and life science industry experience to Provention and, as Chief Financial Officer, will be responsible for leading the company’s financial and capital markets activities.

Mr. Drechsler joins Provention after most recently serving as Chief Financial Officer of Insmed Incorporated, a publicly-traded biopharmaceutical company dedicated to improving the lives of patients with orphan pulmonary disease. During his tenure at Insmed, he helped the company raise in excess of $400 million through equity offerings. Prior to Insmed, Mr. Drechsler served as Chief Financial Officer for VaxInnate Corporation, a privately-held company that developed vaccines for infectious diseases, including seasonal and pandemic flu. There, he played a critical role in securing approximately $200 million in U.S. government funding for the company’s vaccine programs. Before joining VaxInnate, Mr. Drechsler served as Chief Financial Officer for Valera Pharmaceuticals where he helped Valera raise $35 million through an initial public offering.

Mr. Drechsler received a BS in Accountancy from Villanova University, graduating Magna Cum Laude. He obtained his Certified Public Accountant in the State of New Jersey and actively raises funds for and awareness of juvenile diabetes via the JDRF.

Jason Hoitt

Chief Commercial Officer

Jason Hoitt

Chief Commercial Officer

Jason Hoitt brings 18 years of commercial experience in the biotechnology sector to Provention. As our Chief Commercial Officer, Mr. Hoitt is responsible for the development and execution of Provention's global commercial strategy for PRV-031 (teplizumab) and the rest of our pipeline.

Prior to joining Provention, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals (acquired by Swedish Orphan Biovitrum AB, or Sobi) and led all commercial efforts including the pre-launch and launch strategy and execution for DOPTELET ® (avatrombopag) targeting chronic immune thrombocytopenia. Prior to Dova Pharmacetucials, Mr. Hoitt was a member of the commercial leadership team at Insmed Incorporated, serving as a Vice President and Head of Sales.

Mr. Hoitt has held sales, marketing and medical affairs leadership roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences and has been instrumental in the launches and success of DOPTELET (Dova), Arikayce (Insmed), Exondys 51 (Sarepta), and Incivek (Vertex).

Mr. Hoitt holds a B.A. from the College of the Holy Cross.

Heidy Abreu King-Jones

Chief Legal Officer

Heidy Abreu King-Jones

Chief Legal Officer

Heidy King-Jones brings nearly 12 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. As our Chief Legal Officer, Ms. King-Jones will support the company’s commitment to upholding the best practices of compliance, corporate governance, legal and enterprise risk management. Prior to joining Provention, Ms. King-Jones was Senior Vice President, General Counsel and Corporate Secretary at Axcella Health Inc. where she led the legal work for the Axcella’s initial public offering, initial regulatory interactions with FDA and built Axcella’s legal team. Prior to Axcella, Ms. King-Jones managed the Corporate Law Department and was lead commercial counsel at Sarepta Therapeutics, Inc. She was also on Sarepta’s promotional review committee, medical review committee, 401(K) committee and the sponsorship and grants committees. Ms. King-Jones was the legal lead in Sarepta’s commercial readiness working group (responsible for negotiating and finalizing key commercial contracts and developing Sarepta’s commercial compliance program and policies) and global expansion efforts.

Prior to joining Sarepta, Ms. King-Jones was an associate in the Securities and Public Company practice group at Ropes & Gray LLP where she focused her practice on representing public companies in corporate matters including mergers, acquisitions, corporate governance issues, SEC filings and compliance matters, initial public offerings and sales of common stock, bonds, debentures and notes. She has experience representing clients in various industries including the utility, technology, retail and pharmaceutical industries. At Ropes & Gray LLP, Ms. King-Jones also represented pro bono clients on asylum, immigration, medical and housing matters.

Ms. King-Jones holds a J.D. and LL.M in International and Comparative Law from Cornell Law School and a B.A. in Psychology and Sociology from Dartmouth College.